Health Condition 1: D519- Vitamin B12 deficiency anemia, unspecified
Conditions
Interventions
Intervention1: oral b12: Group B (oral therapy)will be treated with 1000 microgram oral vitamin B12 (cyanocobalamine) daily for 1 month.
Control Intervention1: parenteral vitamin b12: After randomizat
Sponsors
Government medical college and hospital
Eligibility
Inclusion criteria
Inclusion criteria: 1) Children of age group - 6 months to 18 years 2) Anemia as defined by WHO. 6-59 months â?? less than 110 g/l at sea level 5-11 yearsâ?? less than 115 g/l at sea level 12-14 yearsâ?? less than 120 g/l at sea level More than 15 yearsâ?? less than 130 g/l at sea level25 Corrected haemoglobin concentration according to sea level correction factor for altitude. 3) Serum vitamin B12 levels below 350 pg/ml OR Holotranscobalamin levels below 35 pmol/l 22,26 will be included in
Exclusion criteria
Exclusion criteria: 1. Children who have already received Vitamin B12. 2. Children who are already taking micronutrient supplementation. 3. Children with iron deficiency anemia (Iron deficiency will be defined by serum ferritin 4. Children who have received blood transfusion within last 1month.12 5. Any critical illness with hemodynamic compromise or on life support measures.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Biochemical parameters- a) Difference in serum vitamin B12 levels after one week and one month of therapy from baseline levels in both oral and intramuscular groups. b) Difference in holotranscobalamin levels after one week and one month of therapy from baseline levels in both oral and intramuscular groups. c) Difference in serum homocysteine levels after one week and one month of therapy from baseline levels in both oral and intramuscular groups 2. Haematological parameters- These will be reassessed as done at enrollment after one week and one month of therapy from baseline levels in both oral and intramuscular groups. Differences from baseline in all these parameters will be assessed at 1 week and 1 month of therapy. 3. Clinical parameters-Clinical improvement in the form of subjective improvement in weakness, fatigue , anorexia, failure to thrive, pallor and irritability after 1 month of therapy with vitamin B12 in both oral and intramuscular groups .Timepoint: For biochemical and haematological parameters- Day 1, 1 week, 1 month clinical -day 1 and 1 month | — |
Secondary
| Measure | Time frame |
|---|---|
| clinical improvement in the form of subjective improvement in weakness, fatigue , anorexia. failure to thrive and irritabilityTimepoint: day 1 and after 1 month of the therapy | — |
Countries
India
Contacts
Public ContactGeetanjali Jindal
Government Medical College and Hospital, Sector 32, Chandigarh
Outcome results
None listed